Abstract
Bovine anaplasmosis, caused by the rickettsia Anaplasma marginale, is an economically important tick-borne disease of cattle that is found worldwide. Its clinical effects of severe anemia, decreased growth, weight loss, and death negatively impact cattle welfare and create a significant economic burden for cattle producers. Despite availability of highly sensitive and specific assays for anti-A. marginale antibodies (competitive ELISA) and A. marginale genetic material (real-time PCR), the interpretation of test results for the diagnosis of clinical anaplasmosis in cattle remains challenging. Treatment and control usually consist of administration of oral and/or injectable tetracyclines; however, this approach is unlikely to be sustainable in the face of increasing scrutiny of antimicrobial usage in livestock. Statistically robust prospective studies are needed to characterize the prevalence, distribution, and transmission of bovine anaplasmosis under field conditions, as the epidemiology of this disease remains incompletely understood. Apart from minimizing exposure of naïve cattle to carriers (e.g., testing new introductions and interpreting in the context of herd-level seropositivity, changing needles between cattle), veterinarians and producers have few tools for prevention of bovine anaplasmosis based on data-driven risk assessment. A vaccine that is consistently safe and effective has proved elusive, but ongoing research into A. marginale vaccine candidates offers hope for a more effective means of protecting cattle from this costly disease.